Clinical Report: Could Isotretinoin Shorten Adult Height?
Overview
A nationwide Danish study involving 379,196 individuals found no clinically meaningful reductions in adult height associated with adolescent isotretinoin treatment for acne, specifically addressing concerns in this population. The findings provide reassurance regarding the safety of isotretinoin in relation to growth.
Background
Concerns about isotretinoin's potential impact on growth have persisted among clinicians and patients, particularly regarding its use in adolescents. Understanding whether isotretinoin affects adult height is crucial for informed decision-making in acne management. This study addresses these concerns with robust data from a large population.
Data Highlights
| Group | Adjusted Mean Height Difference (cm) |
|---|---|
| Men (Isotretinoin Users) | 0.3 |
| Women (Isotretinoin Users) | 0.3 |
| Men (Reference Group) | 180 |
| Women (Reference Group) | 168 |
Key Findings
- No clinically meaningful height reduction was observed in isotretinoin users compared to non-users.
- Adjusted mean height differences were 0.3 cm for both men and women, below the 5 cm threshold for clinical relevance.
- Height differences remained insignificant across various age at first isotretinoin prescription and cumulative dose analyses.
- Stunting prevalence was slightly lower in isotretinoin users (1.5%) compared to the reference group (2.1%), but this should not be interpreted as a protective effect; it may reflect differences in health care access.
- Height was measured by medical staff, enhancing the reliability of the outcome data.
- Findings support the absence of a dose-response relationship between isotretinoin exposure and adult height.
Clinical Implications
These findings may alleviate concerns regarding growth impairment in adolescents treated with isotretinoin for severe acne. Clinicians can confidently prescribe isotretinoin, focusing on its benefits for acne management while engaging in shared decision-making with patients and families.
Conclusion
The study provides strong evidence that isotretinoin does not adversely affect adult height, reinforcing its safety profile in adolescent acne treatment. However, caution is warranted in interpreting results, particularly regarding early initiation of treatment. This knowledge can guide clinical practice and patient discussions.
Related Resources & Content
- Sigrun Alba Johannesdottir Schmidt, JAMA Dermatology, 2026 -- Could Isotretinoin Shorten Adult Height?
- American Academy of Dermatology, JAAD 2024 -- Updated Guidelines for Acne Management
- The Journal of Clinical Endocrinology & Metabolism, 2025 -- Anastrozole Enhances Growth Outcomes in Pediatric Patients with Congenital Adrenal Hyperplasia
- The Journal of Clinical Endocrinology & Metabolism, 2026 -- Impact of GnRH Analogues and Gender-Affirming Hormone Therapy on Adult Height in Transgender Adolescents
- The Journal of Clinical Endocrinology & Metabolism, 2026 -- The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents
- Drugs - Real World Outcomes — Adherence to Contraceptive Guidelines During Isotretinoin Treatment Among Reproductive-Aged Women in Estonia from 2012 to 2016
- New online first articles from JAMA Dermatology
- The effect of isotretinoin treatment for acne vulgaris on height in adolescents: A retrospective cohort study using the Rochester Epidemiology Project
- American Academy of Dermatology issues updated guidelines for the management of acne
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
